Metraipolis › archive › dc_429c8d37d4c5

Concurrent Dual Biologic Therapy (Infliximab-Risankizumab and Dupilumab-Rituximab) for Complex Treatment-Refractory Dermatologic Disease: A Two-Patient Case… — Europe PMC PMID:42923331

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42923331
DOI
10.1159/cde/abvag004
License (as archived)
solo-consultazione
Archived
2026-11-07T04:46:27.041Z
SHA-256 of the archived text
9ded1f643cb3ae05ee0dbc6320f51c11b4d3a74860b3444ded66f1eb3653aef0
Stable URL of this page
https://metraipolis.com/documento/dc_429c8d37d4c5

How to cite

Concurrent Dual Biologic Therapy (Infliximab-Risankizumab and Dupilumab-Rituximab) for Complex Treatment-Refractory Dermatologic Disease: A Two-Patient Case… — Europe PMC PMID:42923331 — Europe PMC (en), https://europepmc.org/article/MED/42923331 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_429c8d37d4c5 (Metraipolis archive dc_429c8d37d4c5, sha256 9ded1f643cb3ae05ee0dbc6320f51c11b4d3a74860b3444ded66f1eb3653aef0)
BibTeX
@misc{dc429c8d37d4c5,
  title = {Concurrent Dual Biologic Therapy (Infliximab-Risankizumab and Dupilumab-Rituximab) for Complex Treatment-Refractory Dermatologic Disease: A Two-Patient Case… — Europe PMC PMID:42923331},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42923331},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_429c8d37d4c5; sha256 9ded1f643cb3ae05ee0dbc6320f51c11b4d3a74860b3444ded66f1eb3653aef0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42923331. Agents can read the archived copy with the MCP tool read_document.